|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1998-1-29
|
|
pubmed:abstractText |
This open-label study enrolled five subjects with biopsy-proven cirrhosis and moderate to severe hepatic impairment (Child-Pugh classification grade B or C) and five age- and gender-matched controls. All subjects received a single 40-mg oral dose of stavudine (d4T). Stavudine pharmacokinetics in subjects with hepatic impairment were similar to those in age- and gender-matched control subjects and were not substantially different from those previously observed in human immunodeficiency virus-infected patients. Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-1244564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-1296235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-1323615,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-1328267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-2734585,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-4541913,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-6533298,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-7252794,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-7861015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-7861017,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-8285815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9420063-8861550
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2793-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9420063-Administration, Oral,
pubmed-meshheading:9420063-Adult,
pubmed-meshheading:9420063-Anti-HIV Agents,
pubmed-meshheading:9420063-Drug Administration Schedule,
pubmed-meshheading:9420063-Female,
pubmed-meshheading:9420063-Humans,
pubmed-meshheading:9420063-Liver Cirrhosis,
pubmed-meshheading:9420063-Male,
pubmed-meshheading:9420063-Middle Aged,
pubmed-meshheading:9420063-Stavudine
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-5554, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
